Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL CELIAC DISEASE TREATMENT MARKET, BY TREATMENT
6.1. Overview
6.2. Gluten-Free Diet
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.1 Gluten-Free Bakery Products
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.2 Gluten-Free Baby Food
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.3 Gluten-Free Pasta
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.4 Gluten-Free Meals
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Vitamin and Mineral Supplements
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Medications
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4.1 Azathioprine
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4.2 Budesonide
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7. GLOBAL CELIAC DISEASE TREATMENT MARKET, BY END USER
7.1. Overview
7.2. Hospitals & Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Clinical Research Organizations
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Academic Institutes
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8. GLOBAL CELIAC DISEASE TREATMENT MARKET, BY REGION
8.1. Overview
8.2. Americas
8.2.1. North America
8.2.1.1. US
8.2.1.2. Canada
8.2.2. Latin America
8.3. Europe
8.3.1. Western Europe
8.3.1.1. Germany
8.3.1.2. France
8.3.1.3. Italy
8.3.1.4. Spain
8.3.1.5. UK
8.3.1.6. Rest of Western Europe
8.3.2. Eastern Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle East & Africa
8.5.1. Middle East
8.5.2. Africa
9. COMPANY LANDSCAPE
9.1.1. Overview
9.1.2. Competitive Analysis
10. COMPANY PROFILES
10.1. Amgen Inc. (US)
10.1.1. Company Overview
10.1.2. Type Overview
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Amneal Pharmaceuticals LLC (US)
10.2.1. Company Overview
10.2.2. Type Overview
10.2.3. Financial Overview
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. BioLineRx (Israel)
10.3.1. Company Overview
10.3.2. Type Overview
10.3.3. Financial Overview
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Calypso Biotech SA (Switzerland)
10.4.1. Company Overview
10.4.2. Type Overview
10.4.3. Financial Overview
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Freedom Foods Group Limited (Australia)
10.5.1. Company Overview
10.5.2. Type Overview
10.5.3. Financial Overview
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. General Mills, Inc. (US)
10.6.1. Company Overview
10.6.2. Type Overview
10.6.3. Financial Overview
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Glenmark Pharmaceuticals Inc. (India)
10.7.1. Company Overview
10.7.2. Type Overview
10.7.3. Financial Overview
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Hain Celestial Group, Inc. (US)
10.8.1. Company Overview
10.8.2. Type Overview
10.8.3. Financial Overview
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Innovate Biopharmaceuticals Inc. (US)
10.9.1. Company Overview
10.9.2. Type Overview
10.9.3. Financial Overview
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Kellogg Company (US)
10.10.1. Company Overview
10.10.2. Type Overview
10.10.3. Financial Overview
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. Mondelez International Inc. (US)
10.11.1. Company Overview
10.11.2. Type Overview
10.11.3. Financial Overview
10.11.4. Key Developments
10.11.5. SWOT Analysis
10.11.6. Key Strategies
10.12. Mylan Pharmaceuticals Inc. (US)
10.12.1. Company Overview
10.12.2. Type Overview
10.12.3. Financial Overview
10.12.4. Key Developments
10.12.5. SWOT Analysis
10.12.6. Key Strategies
10.13. Pinnacle Foods, Inc. (US)
10.13.1. Company Overview
10.13.2. Type Overview
10.13.3. Financial Overview
10.13.4. Key Developments
10.13.5. SWOT Analysis
10.13.6. Key Strategies
10.14. Selecta Biosciences, Inc (US)
10.14.1. Company Overview
10.14.2. Type Overview
10.14.3. Financial Overview
10.14.4. Key Developments
10.14.5. SWOT Analysis
10.14.6. Key Strategies
10.15. Takeda Pharmaceutical Company Ltd (Japan)
10.15.1. Company Overview
10.15.2. Type Overview
10.15.3. Financial Overview
10.15.4. Key Developments
10.15.5. SWOT Analysis
10.15.6. Key Strategies
10.16. The Kraft Heinz Company (US)
10.16.1. Company Overview
10.16.2. Type Overview
10.16.3. Financial Overview
10.16.4. Key Developments
10.16.5. SWOT Analysis
10.16.6. Key Strategies
10.17. West-Ward Pharmaceutical (US)
10.17.1. Company Overview
10.17.2. Type Overview
10.17.3. Financial Overview
10.17.4. Key Developments
10.17.5. SWOT Analysis
10.17.6. Key Strategies
10.18. Zedira GmbH (Germany)
10.18.1. Company Overview
10.18.2. Type Overview
10.18.3. Financial Overview
10.18.4. Key Developments
10.18.5. SWOT Analysis
10.18.6. Key Strategies
10.19. Zydus Pharmaceuticals Inc. (US)
10.19.1. Company Overview
10.19.2. Type Overview
10.19.3. Financial Overview
10.19.4. Key Developments
10.19.5. SWOT Analysis
10.19.6. Key Strategies
10.20. Others
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL CELIAC DISEASE TREATMENT MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL CELIAC DISEASE TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL CELIAC DISEASE TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 6 NORTH AMERICA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 7 NORTH AMERICA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 8 US: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 9 US: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 10 CANADA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 11 CANADA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 12 LATIN AMERICA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 13 LATIN AMERICA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 14 EUROPE: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 15 EUROPE: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 16 WESTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 17 WESTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 18 EASTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 19 EASTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 21 ASIA-PACIFIC: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CELIAC DISEASE TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CELIAC DISEASE TREATMENT MARKET
FIGURE 4 GLOBAL CELIAC DISEASE TREATMENT MARKET SHARE, BY TREATMENT, 2020 (%)
FIGURE 5 GLOBAL CELIAC DISEASE TREATMENT MARKET SHARE, BY END USER, 2020 (%)
FIGURE 6 GLOBAL CELIAC DISEASE TREATMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7AMERICAS: CELIAC DISEASE TREATMENT MARKET SHARE BY REGION, 2020 (%)
FIGURE 7 NORTH AMERICA: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 8 EUROPE: CELIAC DISEASE TREATMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 WESTERN EUROPE: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 10 ASIA-PACIFIC: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 MIDDLE EAST & AFRICA: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 GLOBAL CELIAC DISEASE TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 13 AMGEN INC.: KEY FINANCIALS
FIGURE 14 AMGEN INC.: SEGMENTAL REVENUE
FIGURE 15 AMGEN INC.: REGIONAL REVENUE
FIGURE 16 AMNEAL PHARMACEUTICALS LLC: KEY FINANCIALS
FIGURE 17 AMNEAL PHARMACEUTICALS LLC: SEGMENTAL REVENUE
FIGURE 18 AMNEAL PHARMACEUTICALS LLC: REGIONAL REVENUE
FIGURE 19 BIOLINERX: KEY FINANCIALS
FIGURE 20 BIOLINERX: SEGMENTAL REVENUE
FIGURE 21 BIOLINERX: REGIONAL REVENUE
FIGURE 22 CALYPSO BIOTECH SA: KEY FINANCIALS
FIGURE 23 CALYPSO BIOTECH SA: SEGMENTAL REVENUE
FIGURE 24 CALYPSO BIOTECH SA: REGIONAL REVENUE
FIGURE 25 FREEDOM FOODS GROUP LIMITED: KEY FINANCIALS
FIGURE 26 FREEDOM FOODS GROUP LIMITED: SEGMENTAL REVENUE
FIGURE 27 FREEDOM FOODS GROUP LIMITED: REGIONAL REVENUE
FIGURE 28 GENERAL MILLS, INC.: KEY FINANCIALS
FIGURE 29 GENERAL MILLS, INC.: SEGMENTAL REVENUE
FIGURE 30 GENERAL MILLS, INC.: REGIONAL REVENUE
FIGURE 31 GLENMARK PHARMACEUTICALS INC.: KEY FINANCIALS
FIGURE 32 GLENMARK PHARMACEUTICALS INC.: SEGMENTAL REVENUE
FIGURE 33 GLENMARK PHARMACEUTICALS INC.: REGIONAL REVENUE
FIGURE 34 HAIN CELESTIAL GROUP, INC.: KEY FINANCIALS
FIGURE 35 HAIN CELESTIAL GROUP, INC.: SEGMENTAL REVENUE
FIGURE 36 HAIN CELESTIAL GROUP, INC.: REGIONAL REVENUE
FIGURE 37 INNOVATE BIOPHARMACEUTICALS INC.: KEY FINANCIALS
FIGURE 38 INNOVATE BIOPHARMACEUTICALS INC.: SEGMENTAL REVENUE
FIGURE 39 INNOVATE BIOPHARMACEUTICALS INC.: REGIONAL REVENUE
FIGURE 40 KELLOGG COMPANY: KEY FINANCIALS
FIGURE 41 KELLOGG COMPANY: SEGMENTAL REVENUE
FIGURE 42 KELLOGG COMPANY: REGIONAL REVENUE
FIGURE 43 MONDELEZ INTERNATIONAL INC.: KEY FINANCIALS
FIGURE 44 MONDELEZ INTERNATIONAL INC.: SEGMENTAL REVENUE
FIGURE 45 MONDELEZ INTERNATIONAL INC.: REGIONAL REVENUE
FIGURE 46 MYLAN PHARMACEUTICALS INC.: KEY FINANCIALS
FIGURE 47 MYLAN PHARMACEUTICALS INC.: SEGMENTAL REVENUE
FIGURE 48 MYLAN PHARMACEUTICALS INC.: REGIONAL REVENUE
FIGURE 49 PINNACLE FOODS, INC.: KEY FINANCIALS
FIGURE 50 PINNACLE FOODS, INC.: SEGMENTAL REVENUE
FIGURE 51 PINNACLE FOODS, INC.: REGIONAL REVENUE
FIGURE 52 SELECTA BIOSCIENCES, INC: KEY FINANCIALS
FIGURE 53 SELECTA BIOSCIENCES, INC: SEGMENTAL REVENUE
FIGURE 54 SELECTA BIOSCIENCES, INC: REGIONAL REVENUE
FIGURE 55 TAKEDA PHARMACEUTICAL COMPANY LTD: KEY FINANCIALS
FIGURE 56 TAKEDA PHARMACEUTICAL COMPANY LTD: SEGMENTAL REVENUE
FIGURE 57 TAKEDA PHARMACEUTICAL COMPANY LTD: REGIONAL REVENUE
FIGURE 58 THE KRAFT HEINZ COMPANY: KEY FINANCIALS
FIGURE 59 THE KRAFT HEINZ COMPANY: SEGMENTAL REVENUE
FIGURE 60 THE KRAFT HEINZ COMPANY: REGIONAL REVENUE
FIGURE 61 WEST-WARD PHARMACEUTICAL: KEY FINANCIALS
FIGURE 62 WEST-WARD PHARMACEUTICAL: SEGMENTAL REVENUE
FIGURE 63 WEST-WARD PHARMACEUTICAL: REGIONAL REVENUE
FIGURE 64 ZEDIRA GMBH: KEY FINANCIALS
FIGURE 65 ZEDIRA GMBH: SEGMENTAL REVENUE
FIGURE 66 ZEDIRA GMBH: REGIONAL REVENUE
FIGURE 67 ZYDUS PHARMACEUTICALS INC.: KEY FINANCIALS
FIGURE 68 ZYDUS PHARMACEUTICALS INC.: SEGMENTAL REVENUE
FIGURE 69 ZYDUS PHARMACEUTICALS INC.: REGIONAL REVENUE